subject area of
- BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase Academic Article
- Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era Academic Article
- Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance Academic Article
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma Academic Article
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib Academic Article
- Exon-skipping in BCR/ABL is induced by ABL exon 2 Academic Article
- Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia Academic Article
- Gender andBCR-ABLtranscript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia Academic Article
- Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia Academic Article
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Academic Article
- Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All? Academic Article
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013 Conference Paper